Methods for determining responsiveness to a dihydrofolate reductase inhibitor
AssigneeTargeted Molecular Diagnostics, LLC
InventorsSarah Bacus, Diarmuid Moran
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for predicting or determining the sensitivity of a cell and/or biological sample obtained from a subject to a DHFR inhibitor including, for example, an antifolate such as Methotrexate or Pemetrexed. Such methods may comprise determining the expression level of one or more miRNAs (e.g., one or more members of the miR-181 and/or miR-143 families) in a cell or biological sample. The methods may be used to determine the responsiveness of a subject to treatment with a DHFR inhibitor.
Claims21
A method for determining sensitivity of a test cell to a dihydrofolate reductase (DHFR) inhibitor, the method comprising:
- a. contacting a test cell with a DHFR inhibitor;
- b. assaying the test cell for expression of one or more miRNAs;
- c. determining if expression of the one or more miRNAs in the test cell is elevated or reduced compared to a control cell or above or below a threshold;
- and
- d. employing the determination of the expression of the one or more miRNAs in the test cell to determine sensitivity of the test cell to the DHFR inhibitor,
- wherein the test cell has mutated RAS and no amplification of the RAS gene.
A method for screening one or more dihydrofolate reductase (DHFR) inhibitors for a pharmacological activity, the method comprising:
- a. contacting a test cell with the one or more DHFR inhibitors;
- b. assaying the contacted test cell for expression of one or more miRNAs;
- c. determining if expression of the one or more miRNAs in the test cell is elevated or reduced compared to a control cell or above or below a threshold;
- and
- d. employing the determination of the expression of the one or more miRNAs in the test cell to determine a pharmacological activity of the DHFR inhibitor,
- wherein the test cell has mutated RAS and no amplification of the RAS gene.
19-35. (canceled)
A method for determining responsiveness of a subject with a disease or disorder to a dihydrofolate reductase (DHFR) inhibitor, the method comprising:
- a. administering a DHFR inhibitor to the subject;
- b. obtaining a biological sample from the subject;
- c. assaying the biological sample for expression of one or more miRNAs;
- d. determining if expression of the one or more miRNAs in the biological sample is elevated or reduced compared to a control sample or above or below a threshold;
- and
- e. employing the determination of the expression of the one or more miRNAs in the biological sample to determine responsiveness of the subject to the DHFR inhibitor,
- wherein the biological sample comprises cells with mutated RAS and no amplification of the RAS gene.
37-56. (canceled)
Dependencies are inferred from the claim text.